Studies have shown that lipid synthesis can be reduced by regulating the AMPK/SREBP-1c/ACC signaling pathway, thereby delaying the development of MASLD [7,8]. The gene discussed is SREBF1; the disease is metabolic dysfunction-associated steatotic liver disease.